Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Supplementary cash flow information - Other Operating Assets and Liabilities (Details)

v3.19.3.a.u2
Supplementary cash flow information - Other Operating Assets and Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Supplementary Cash Flow Information [Abstract]    
Accounts receivable and accrued interest receivable $ (151) $ (108)
Prepaid expenses and deposits (1,975) (5,094)
Adjustments for increase (decrease) in clinical trail deposits 149 90
Clinical trial contract deposits 4,106 (888)
Net change in other operating assets and liabilities (note 17) 2,129 (6,000)
Interest received $ 2,619 $ 2,148